JP6668264B2 - 複数のレトロウイルス株における非対称標的部位を組み換えるための、十分に寛容化され高度に特異的なテーラーメイドリコンビナーゼ - Google Patents
複数のレトロウイルス株における非対称標的部位を組み換えるための、十分に寛容化され高度に特異的なテーラーメイドリコンビナーゼ Download PDFInfo
- Publication number
- JP6668264B2 JP6668264B2 JP2016575647A JP2016575647A JP6668264B2 JP 6668264 B2 JP6668264 B2 JP 6668264B2 JP 2016575647 A JP2016575647 A JP 2016575647A JP 2016575647 A JP2016575647 A JP 2016575647A JP 6668264 B2 JP6668264 B2 JP 6668264B2
- Authority
- JP
- Japan
- Prior art keywords
- recombinase
- sequence
- tailor
- site
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010091086 Recombinases Proteins 0.000 title claims description 307
- 102000018120 Recombinases Human genes 0.000 title claims description 307
- 230000006798 recombination Effects 0.000 title claims description 48
- 238000005215 recombination Methods 0.000 title claims description 48
- 241001430294 unidentified retrovirus Species 0.000 title claims description 33
- 210000004027 cell Anatomy 0.000 claims description 105
- 150000007523 nucleic acids Chemical class 0.000 claims description 73
- 108020004414 DNA Proteins 0.000 claims description 68
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 44
- 230000001566 pro-viral effect Effects 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 206010038997 Retroviral infections Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108091093088 Amplicon Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 94
- 239000002773 nucleotide Substances 0.000 description 68
- 125000003729 nucleotide group Chemical group 0.000 description 65
- 208000031886 HIV Infections Diseases 0.000 description 51
- 239000013598 vector Substances 0.000 description 48
- 239000013604 expression vector Substances 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 38
- 125000006850 spacer group Chemical group 0.000 description 35
- 230000001177 retroviral effect Effects 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 239000000758 substrate Substances 0.000 description 25
- 230000003612 virological effect Effects 0.000 description 25
- 241000725303 Human immunodeficiency virus Species 0.000 description 24
- 210000005260 human cell Anatomy 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 239000003550 marker Substances 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 108091035707 Consensus sequence Proteins 0.000 description 15
- 108010051219 Cre recombinase Proteins 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 230000004927 fusion Effects 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 238000002818 protein evolution Methods 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 210000004504 adult stem cell Anatomy 0.000 description 9
- 108010064672 Tre-Recombinase Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010061833 Integrases Proteins 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 108010052160 Site-specific recombinase Proteins 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 101710205625 Capsid protein p24 Proteins 0.000 description 6
- 241000713730 Equine infectious anemia virus Species 0.000 description 6
- 241000713800 Feline immunodeficiency virus Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 6
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 6
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 101710177166 Phosphoprotein Proteins 0.000 description 6
- 241000713311 Simian immunodeficiency virus Species 0.000 description 6
- 101710149279 Small delta antigen Proteins 0.000 description 6
- 102220525770 Sodium channel subunit beta-3_Q89L_mutation Human genes 0.000 description 6
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 5
- 108700010070 Codon Usage Proteins 0.000 description 5
- 241000560067 HIV-1 group M Species 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 241000713325 Visna/maedi virus Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000714266 Bovine leukemia virus Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 4
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000005934 immune activation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 3
- 241001663879 Deltaretrovirus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000714165 Feline leukemia virus Species 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 241001466984 Simian T-lymphotropic virus 1 Species 0.000 description 3
- 241000713675 Spumavirus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102220485974 Dihydropteridine reductase_S51T_mutation Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102000012330 Integrases Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000721267 Macara Species 0.000 description 2
- 102220490328 Matrix metalloproteinase-27_M30V_mutation Human genes 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000863430 Shewanella Species 0.000 description 2
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102200024525 rs11543022 Human genes 0.000 description 2
- 102200067350 rs118203990 Human genes 0.000 description 2
- 102220337910 rs1553612598 Human genes 0.000 description 2
- 102220028387 rs202181932 Human genes 0.000 description 2
- 102220135761 rs61731517 Human genes 0.000 description 2
- 102200055259 rs723044 Human genes 0.000 description 2
- 102220227356 rs777753452 Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241001664176 Alpharetrovirus Species 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001231757 Betaretrovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 241001663878 Epsilonretrovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150101654 PSR1 gene Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102220492129 Protein Flattop_V23A_mutation Human genes 0.000 description 1
- 108010087512 R recombinase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101710200251 Recombinase cre Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 108010010574 Tn3 resolvase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000009420 retrofitting Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 102220082323 rs35269563 Human genes 0.000 description 1
- 102220231640 rs749720760 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14183277.4A EP2993229A1 (fr) | 2014-09-02 | 2014-09-02 | Recombinase bien toléré et très spécifique mise au point sur mesure pour recombiner des sites asymétriques voulus dans une pluralité de souches de rétrovirus |
EP14183277.4 | 2014-09-02 | ||
PCT/EP2015/069890 WO2016034553A1 (fr) | 2014-09-02 | 2015-09-01 | Recombinase bien tolérée et hautement spécifique conçue sur mesure pour recombiner des sites cibles asymétriques dans une pluralité de souches de rétrovirus |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017526341A JP2017526341A (ja) | 2017-09-14 |
JP6668264B2 true JP6668264B2 (ja) | 2020-03-18 |
Family
ID=51518540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016575647A Active JP6668264B2 (ja) | 2014-09-02 | 2015-09-01 | 複数のレトロウイルス株における非対称標的部位を組み換えるための、十分に寛容化され高度に特異的なテーラーメイドリコンビナーゼ |
Country Status (11)
Country | Link |
---|---|
US (1) | US10150953B2 (fr) |
EP (2) | EP2993229A1 (fr) |
JP (1) | JP6668264B2 (fr) |
CN (2) | CN113699172A (fr) |
AU (1) | AU2015310965B2 (fr) |
CA (1) | CA2951772C (fr) |
ES (1) | ES2710708T3 (fr) |
HU (1) | HUE040388T2 (fr) |
PL (1) | PL3143136T3 (fr) |
RU (1) | RU2706194C2 (fr) |
WO (1) | WO2016034553A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2576798B1 (fr) | 2010-05-27 | 2016-04-27 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | Recombinase mise au point sur mesure pour recombiner des sites asymétriques voulus dans une pluralité de souches de rétrovirus |
CN110914414A (zh) * | 2017-06-14 | 2020-03-24 | 德累斯顿工业大学 | 利用设计dna重组酶遗传改变基因组的方法与手段 |
WO2021085580A1 (fr) * | 2019-10-31 | 2021-05-06 | 国立研究開発法人理化学研究所 | Polynucléotide et son utilisation |
EP3831939A1 (fr) | 2019-12-06 | 2021-06-09 | Technische Universität Dresden | Fusion de recombinases spécifiques à un site pour une édition efficace et spécifique du génome |
CN111304211B (zh) * | 2020-03-10 | 2020-12-01 | 无锡市第五人民医院 | Rhd-t268a突变体及其检测 |
CN118234856A (zh) | 2021-11-15 | 2024-06-21 | 德累斯顿工业大学 | 用于有效且特异性基因组编辑的位点特异性重组酶 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE317440T1 (de) | 1997-11-18 | 2006-02-15 | Pioneer Hi Bred Int | Neuartige methode zur integration von fremd-dna ins eukaryotische genom |
US6890726B1 (en) | 1999-04-06 | 2005-05-10 | Oklahoma Medical Research Foundation | Method for selecting recombinase variants with altered specificity |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
GB0029375D0 (en) | 2000-12-01 | 2001-01-17 | Total Fina Elf | Substrate linked directed evolution (slide) |
WO2005081632A2 (fr) | 2004-02-26 | 2005-09-09 | State Of Israel, Ministry Of Agriculture, Agricultural Research Organization | Enzymes, cellules et procedes de recombinaison specifiques de sites dans des sites asymetriques |
US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
EP1942192A1 (fr) | 2007-01-08 | 2008-07-09 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Utilisation de la récombinase sur mesure dans le traitement des infection retrovirales |
WO2009007982A1 (fr) | 2007-07-11 | 2009-01-15 | State Of Israel, Ministry Of Agriculture, Agricultural Research Organization | Région conservée du génome du vih-1 et utilisations de celle-ci |
EP2576798B1 (fr) * | 2010-05-27 | 2016-04-27 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | Recombinase mise au point sur mesure pour recombiner des sites asymétriques voulus dans une pluralité de souches de rétrovirus |
-
2014
- 2014-09-02 EP EP14183277.4A patent/EP2993229A1/fr not_active Withdrawn
-
2015
- 2015-09-01 RU RU2016148309A patent/RU2706194C2/ru active
- 2015-09-01 PL PL15756660T patent/PL3143136T3/pl unknown
- 2015-09-01 AU AU2015310965A patent/AU2015310965B2/en active Active
- 2015-09-01 WO PCT/EP2015/069890 patent/WO2016034553A1/fr active Application Filing
- 2015-09-01 CN CN202110898897.4A patent/CN113699172A/zh active Pending
- 2015-09-01 CA CA2951772A patent/CA2951772C/fr active Active
- 2015-09-01 EP EP15756660.5A patent/EP3143136B1/fr active Active
- 2015-09-01 JP JP2016575647A patent/JP6668264B2/ja active Active
- 2015-09-01 HU HUE15756660A patent/HUE040388T2/hu unknown
- 2015-09-01 ES ES15756660T patent/ES2710708T3/es active Active
- 2015-09-01 CN CN201580036183.5A patent/CN106852155A/zh active Pending
- 2015-09-01 US US15/317,088 patent/US10150953B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2016148309A3 (fr) | 2019-04-03 |
US10150953B2 (en) | 2018-12-11 |
AU2015310965B2 (en) | 2021-02-25 |
PL3143136T3 (pl) | 2019-02-28 |
EP3143136A1 (fr) | 2017-03-22 |
EP3143136B1 (fr) | 2018-11-07 |
US20170175091A1 (en) | 2017-06-22 |
CN106852155A (zh) | 2017-06-13 |
AU2015310965A1 (en) | 2016-12-15 |
CA2951772C (fr) | 2022-12-13 |
ES2710708T3 (es) | 2019-04-26 |
RU2706194C2 (ru) | 2019-11-14 |
RU2016148309A (ru) | 2018-10-03 |
HUE040388T2 (hu) | 2019-03-28 |
WO2016034553A1 (fr) | 2016-03-10 |
CA2951772A1 (fr) | 2016-03-10 |
JP2017526341A (ja) | 2017-09-14 |
CN113699172A (zh) | 2021-11-26 |
EP2993229A1 (fr) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10316301B2 (en) | Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains | |
JP6668264B2 (ja) | 複数のレトロウイルス株における非対称標的部位を組み換えるための、十分に寛容化され高度に特異的なテーラーメイドリコンビナーゼ | |
EP2094855B1 (fr) | Utilisation des récombinases sur mesure dans le traitement des infection retrovirales | |
JP2019517281A (ja) | 神経セロイドリポフスチン症の遺伝子治療 | |
Class et al. | Patent application title: TAILORED RECOMBINASE FOR RECOMBINING ASYMMETRIC TARGET SITES IN A PLURALITY OF RETROVIRUS STRAINS Inventors: Joachim Hauber (Hamburg, DE) Jan Chemnitz (Oederquart, DE) Frank Buchholz (Dresden, DE) Janet Chusainow (Dresden, DE) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200128 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6668264 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |